MaaT013, a Microbiome Ecosystem Therapy™ (MET), is designed to restore the gut microbiome in pediatric patients aged 6 to 18 years with steroid-resistant aGvHD.
The skin is not merely a protective barrier; it is a complex, dynamic ecosystem populated by billions of microorganisms that play essential roles in maintaining skin health.
Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment.
Positive results from Phase 1 trial of BL-001, an innovative live biotherapeutic product (LBP) designed to replicate the metabolic effects of the ketogenic diet.
A new database of thousands of gut microbiota samples from across the word highlights the need for more diverse microbiota research across the globe.
The approval is major step forward in the fight against recurrent C. diff infection.
Certain features of the vaginal microbiota, including specific bacterial communities, could indicate an increased Chlamydia infection risk.
Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.
David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments.
Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…
